Back to Search Start Over

Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort.

Authors :
IJzerman, Nikki S.
Mohammadi, Mahmoud
Tzanis, Dimitri
Gelderblom, Hans
Fiore, Marco
Fumagalli, Elena
Rutkowski, Piotr
Bylina, Elzbieta
Zavrakidis, Ioannis
Steeghs, Neeltje
Bonenkamp, Han J.
van Etten, Boudewijn
Grünhagen, Dirk J.
Rasheed, Shahnawaz
Tekkis, Paris
Honoré, Charles
van Houdt, Winan
van der Hage, Jos
Bonvalot, Sylvie
Schrage, Yvonne
Source :
European Journal of Surgical Oncology; Jun2020, Vol. 46 Issue 6, p1124-1130, 7p
Publication Year :
2020

Abstract

Rectal gastrointestinal stromal tumours (GISTs) are rare tumours. Variability in the management may influence outcome, but there is a lack of understanding regarding contemporary variance in care. A multicenter, international, retrospective cohort study was performed to elucidate characteristics and outcomes of rectal GIST in European practice, with particular reference to surgical approach. All rectal GIST patients diagnosed between 2009 and 2018 were identified from five European databases. Recurrence free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier method. Possible confounders were identified using Cox regression analyses. From 210 patients, 155 patients had surgery. The three main types of surgery were local tumour resection (LTR, n = 46), low anterior resection (LAR, n = 31) and abdomino-perineal resection (APR, n = 32). Most patients received neoadjuvant (65%) and/or adjuvant imatinib therapy (66%). Local recurrence rate after surgery was 15% and overall recurrence rate 28%. No significant differences were found in terms of RFS nor OS between LTR, LAR and APR. However, locally resected tumours were smaller, while LAR and APR patients more often received perioperative imatinib. General hospitals treated smaller GISTs, offered imatinib less frequently, and had a higher tumour rupture rate. In the multivariate analysis in the group having LTR, APR or LAR, the only significant prognostic factor for local recurrence was higher age (HR 1.06, CI 1.00–1.12, p = 0.048). In European clinical practice for rectal GIST, LTR, LAR and APR have comparable local control. Multimodal approach is higher and tumour rupture less frequent in specialist centres compared to general hospitals. • Rectal GIST is a rare entity of soft tissue sarcoma • Most rectal GISTs are resected surgically and treated with perioperative imatinib • Despite multimodal treatment, the recurrence rate is high • Aspects of care are of higher quality in specialist centres • Referral of rectal GIST to specialist centres is therefore recommended [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
07487983
Volume :
46
Issue :
6
Database :
Supplemental Index
Journal :
European Journal of Surgical Oncology
Publication Type :
Academic Journal
Accession number :
143553874
Full Text :
https://doi.org/10.1016/j.ejso.2020.02.033